MLLTS trial

Multicenter Lymphangioleiomyomatosis Long Term Sirolimus Trial - MLLTS

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1091220037

Enrollment

Registered

2010-03-15

Start date

2011-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lymphangioleiomyomatosis

Interventions

Intervention type:DRUG Name of intervention:sirolimus Dose form / Japanese Medical Device Nomenclature:TABLET Route of administration / Site of application:ORAL Dose per administration:2 2 mg Dosing f

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. LAM patients with definitive diagnosis. 2. patients who is expected to live more than two years. 3. patients who can visit out patient clinic periodically. 4. patients from whom a written informed consent will be obtained.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
All adverse events	—

Secondary

Measure	Time frame
1, adverse events 2, walk distance of 6MT 3, pulmonary function test 4, frequency of pneumothorax or amount of effusion of chylothorax	—

Countries

Japan

Contacts

Public ContactRyushi Tazawa

Niigata University Medical and Dental Hospital

ryushi@med.niigata-u.ac.jp+81-25-227-2022

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026